Biogen’s Upcoming Drug Announcements and Zynga Increased Price Target 📈

Biogen’s Upcoming Drug Announcements and Zynga Increased Price Target


Biogen is a biotechnology company that discovers and manufactures therapies for treating neurological and neurodegenerative diseases. With a market cap of $40.986 billion, they are one of the largest drug manufacturers in the world. Unlike most drug companies, Biogen has been quite flat in the last month, falling 1.21%.

In less than 2 months, the Food and Drug Administration will make a decision about Biogen’s drug “aducanumab”, an Alzheimer therapy. Along with that, new data is likely to arrive on Biogen’s “Zuranolone”, a depression drug that they are developing with Sage Therapeutics. Many are bullish, with analyst Michael Yee writing that if the aducanumab and Zuranolone news are positive, Biogen could possibly rise to $500 per share, and if the opposite takes place, a decrease to around $175 is likely.

Biogen closed at $269.05 on Monday, down 0.47% on the day.


Zynga is a mobile game developing company based in San Francisco, California. Known specifically for their game “Farmville”, they received heavy traffic during the COVID-19 pandemic as many went to mobile games to pass time.

On Tuesday, BMO analyst Gerrick Johnson raised Zynga to an ‘Outperform”, with a Wall-Street high $15 price target. The reasoning was quite simple, with Zynga holding competitive advantages over its competitors along with its superior data analytics. Even as technology is slowing down with the increasing number of vaccinations, many are bullish on Zynga with hopes that the company will continue to flourish post-pandemic.

Zynga closed at $10.59 on Monday, up 0.28% on the day.

I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.


More Posts

Get your daily Invstr Crunch

Get the market news and updates you need, delivered to your inbox or available on our daily podcast.

Risk Disclosure:

Invstr is not a bank and banking services are provided by Vast Bank, N.A.

Brokerage and Banking services are currently only available to U.S. residents.

Invstr app and web services are provided by Invstr Ltd. Advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC) details of which can be obtained here. Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value.

Investing involves risk and can lead to losses. Past performance does not guarantee future results.

Vast Bank N.A. a nationally chartered bank and member of the FDIC, provides the banking products, including the products and services related to digital asset accounts. As with any asset, the value of Digital assets can go up or down and there can be a substantial risk that you lose money buying, holding or investing in digital assets. You should carefully consider whether trading or holding Digital assets is suitable for you in light of your financial condition. Any Digital Assets in your digital asset account are not insured by any government entities, including but not limited to FDIC or SIPC.

The Invstr Visa® Debit Card is issued by Vast Bank, N.A. pursuant to a license from Visa U.S.A Inc and may be used everywhere Visa debit cards are accepted. Invstr Ltd, Invstr Financial LLC and Invstr Securities Ltd are subsidiaries of Marketspringpad Holdings (collectively “Invstr”) and Invstr is solely responsible for the application services and website content.

Watchlists provided when users first access the service are not a recommendation to invest. Instead they are provided to help users better navigate the service. Users are free to edit and create their own watchlists. From time to time, Invstr will suggest instruments solely based on an individual’s interest and the interest levels of the Invstr community.The statistical and portfolio builder models generated by Invstr do not reflect actual investment results and are not guarantees of future results.Comments provided by Invstr leaders, influencers or members of the Invstr Community are not recommendations and should not be construed as such.Invstr does not endorse the content or the positions posted by them. Their investment approach, and that of the models provided by Invstr, may be different from yours and may not be appropriate for you.